Nasdaq:BLTEPublished
Belite Bio Announces Extension of FDA Review Timeline for Tinlarebant NDA
SAN DIEGO, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs,…
